Nehal Mehta
Cardiovascular Disease · Philadelphia, PANPI 1831281591
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $92,251 of the $128,798 with a category attached, or 71.6%. Amgen accounts for 60.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $62,524 and has fallen 83.0% since, to $10,614 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $2044.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$78K
- E.r. Squibb & Sons, L.L.C.$27K
- AbbVie$8K
- Novartis$7K
- LEO Pharma AS$6K
- Johnson & Johnson$2K
- plus $85 from 3 others
Across 6 payments — averaging $51,076 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$290K
- Amgen$12K
- Pfizer$3K
- Bristol Myers Squibb$1K
What the payments were for
- Consulting fees$92,25172%
- Travel & lodging$36,13728%
- Food & beverage$4110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 29 | $77,895 |
| E.r. Squibb & Sons, L.L.C. | 10 | $26,870 |
| AbbVie | 14 | $8,226 |
| Novartis | 3 | $7,099 |
| LEO Pharma AS | 3 | $6,211 |
| Johnson & Johnson | 1 | $2,412 |
| Medtronic | 1 | $45 |
| Novartis Pharma AG | 1 | $35 |
| Itamar Medical Inc | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$128,798 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
- Brian DrachmanPhiladelphia$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.